BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

...NY-ESO-1 and is partnered with GlaxoSmithKline plc (NYSE:GSK; LSE:GSK), IMC-C103C targeting MAGEA4 and IMC-F106C targeting PRAME...
...PMEL17; PMEL) – Silver homologMAGEA4 – Melanoma-associated antigen A4NY-ESO-1 (CTAG1B) – Cancer/testis antigen 1BPRAMEPreferentially expressed antigen in melanoma Lauren...
BioCentury | Mar 2, 2020
Finance

Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline

...the capital would also fund the advancement of two programs into the clinic: IMC-F106C targeting PRAME...
...Immunocore’s platform to treat infectious diseases (see “Immunocore’s Gates Injection” ). Targets CD3 PRAME - Preferentially expressed antigen in melanoma Stephen...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Bispecifics and allogeneics steal the spotlight from autologous CAR Ts

...TCR and a humanized T cell recruiting antibody. A TCER targeting the intracellular tumor antigen PRAME...
...vitro antitumor activity at low picomolar concentrations and inhibits growth in xenograft mouse models of PRAME-expressing...
...complex class I A 2 NKp30 (NCR3; CD337) - Natural killer p30 receptor PRAME - Preferentially expressed antigen in melanoma...
BioCentury | Apr 4, 2019
Company News

Cytovant launches with Asia focus, Medigene deal

...a preclinical T cell immunotherapy targeting NY-ESO-1, and a dendritic cell vaccine containing WT1 and PRAME...
...1 Paul Bonanos, Assistant Editor DC Vaccine containing WT1/PRAME Medigene AG Roivant Sciences GmbH Sinovant Sciences Ltd. Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B) Preferentially expressed antigen in melanoma (PRAME) Wilms...
BioCentury | Sep 8, 2017
Company News

GSK nabs Adaptimmune’s NY-ESO SPEAR T cell therapy program

...targets for TCR programs which Adaptimmune will develop to IND. Earlier this year, GSK selected preferentially expressed antigen in melanoma (PRAME)...
...second target under the deal. Adaptimmune expects preclinical work on the T cell therapy against PRAME...
...June, Eureka Therapeutics Inc. (Emeryville, Calif.) published preclinical data which suggested that TCR-mimicking antibodies targeting PRAME...
BioCentury | Sep 8, 2017
Company News

GSK exercises option for Adaptimmune’s NY-ESO SPEAR T cell therapy program

...targets for TCR programs which Adaptimmune will develop to IND. Earlier this year, GSK selected preferentially expressed antigen in melanoma (PRAME)...
...second target under the deal. Adaptimmune expects preclinical work on the T cell therapy against PRAME...
...June, Eureka Therapeutics Inc. (Emeryville, Calif.) published preclinical data which suggested that TCR-mimicking antibodies targeting PRAME...
BioCentury | Jul 20, 2017
Product R&D

Eureka moment for TCR mimics

...demonstrating that its TCR-mimicking (TCRm) antibodies can recognize and kill cancer cells expressing the intracellular PRAME...
...MHCI - Major histocompatibility complex class I; NY-ESO-1 (CTAG1B) - Cancer/testis antigen 1B; PRAME - Preferentially expressed antigen in melanoma...
...class I MUC16 (CA125) - Mucin 16 NY-ESO-1 (CTAG1B) - Cancer/testis antigen 1B PRAME - Preferentially expressed antigen in melanoma...
BioCentury | Apr 11, 2016
Clinical News

DC Vaccine containing WT1/PRAME: Phase I/II started

...Medigene began an open-label, Norwegian Phase I/II trial to evaluate its DC Vaccine containing WT1/PRAME for...
...Germany Product: DC Vaccine containing WT1/PRAME Business: Cancer Molecular target: Wilms tumor 1 (WT1) ; Preferentially expressed antigen in melanoma (PRAME)...
BioCentury | Jun 1, 2015
Company News

Leiden University, Bellicum deal

...exclusive, worldwide rights to high-affinity T cell receptor (TCR) products targeting solid tumors expressing the preferentially expressed antigen in melanoma (PRAME)...
...product under the deal, BPX-701 , by year end. BPX-701 is a TCR-based therapy targeting PRAME...
BioCentury | Dec 5, 2011
Company News

Abbott, GlaxoSmithKline deal

...Abbott partnered with GlaxoSmithKline to co-develop and commercialize a PCR-based companion diagnostic for GSK's PRAME ASCI...
...and will screen tumors for the expression of the preferentially expressed antigen in melanoma (PRAME) . GSK's cancer vaccine against PRAME...
Items per page:
1 - 10 of 14